Air Liquide, together with its subsidiary VitalAire, is launching a new, personalised support program for sleep apnea patients in France, further building on its increasingly global participation in this field.
A little known disorder which can lead to serious complications, sleep apnea affects 1.5 million people in France, and 5% of the world’s adult population.
The standard treatment for sleep apnea is Continuous Positive Airway Pressure (CPAP), handled daily and in the patient’s home. Air Liquide is a major global player in this field while in Europe, the group provides services for 15% of all patients – working alongside their doctors.
Air Liquide is further strengthening its international position following recent acquisitions in the Netherlands (Comcare Medical) and Tunisia (Air Separation). The group has just opened its first ‘sleep centre’ in China, dedicated to the global care management of patients suffering from sleep apnea, and is now launching the new programme in its native France.
... to continue reading you must be subscribed
